FDA Prepares To Begin Search For Safety Issues At Molecular Level
Executive Summary
FDA is exploring a pharmacological approach for identifying a drug's safety characteristics so sponsors can assess risk earlier in the drug development process
You may also be interested in...
Genomic Data Collection Encouraged, But Not Mandated, For Early Clinical Studies
FDA draft guidance emphasizes importance of pre-specifying DNA sample collection at the start of a clinical program.
FDA Should Ease Criteria For Some Renal Studies, Advisory Cmte. Says
FDA should amend its new renal testing guidance to reflect real-world conditions and ease the burden - in at least one area - for sponsors, according to an FDA advisory committee. With an eye toward facilitating clinical testing, the panel recommended that the agency change its patient selection criteria for one segment of pharmacokinetics studies on the effect of renal impairment on drug dosing
FDA Should Ease Criteria For Some Renal Studies, Advisory Cmte. Says
FDA should amend its new renal testing guidance to reflect real-world conditions and ease the burden - in at least one area - for sponsors, according to an FDA advisory committee. With an eye toward facilitating clinical testing, the panel recommended that the agency change its patient selection criteria for one segment of pharmacokinetics studies on the effect of renal impairment on drug dosing